acquired
Stage
2
Investors
About
Develops next-generation radiopharmaceuticals (radioconjugates) for precision medicine, focused on treating cancer with targeted radioconjugate therapies.
Explore Fusion Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.